OMI · Owens & Minor Inc/Va/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $627.78M | - | $697.26M | $681.92M | $2.63B | - | $2.72B | $2.67B | $2.61B | - |
| Cost of Revenue | $349.75M | - | $375.07M | $357.31M | $2.11B | - | $2.16B | $2.13B | $2.08B | - |
| Gross Profit | $278.03M | - | $322.20M | $324.60M | $526.01M | - | $559.71M | $544.15M | $535.53M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $255.23M | - | $265.84M | $267.85M | $462.35M | - | $469.80M | $469.31M | $477.61M | - |
| Total Operating Expenses | $610.65M | - | $670.79M | $643.48M | - | - | - | - | - | - |
| D&A | $61.74M | - | - | - | $61.15M | - | $61.61M | $63.88M | $74.09M | - |
| Operating Income | $17.13M | - | $26.47M | ($39.71M) | $124.0K | - | $24.20M | $20.30M | $9.70M | - |
| Interest Expense | $24.21M | - | $29.03M | $26.01M | $33.96M | - | $36.55M | $35.90M | $35.66M | - |
| Income Tax | ($9.78M) | - | $1.97M | ($1.13M) | ($10.09M) | - | ($1.02M) | $15.11M | ($5.23M) | - |
| Net Income | ($6.47M) | - | ($150.28M) | ($869.06M) | ($24.98M) | - | ($12.77M) | ($31.91M) | ($21.89M) | - |
| EPS - Basic | ($0.08) | - | ($1.94) | ($11.30) | ($0.32) | - | ($0.17) | ($0.42) | ($0.29) | - |
| EPS - Diluted | ($0.08) | - | ($1.94) | ($11.30) | ($0.32) | - | ($0.17) | ($0.42) | ($0.29) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $336.88M | $281.99M | $32.84M | $38.26M | $59.44M | $49.38M | $45.45M | $243.67M | $244.87M | $243.04M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $65.28M | $74.44M | $63.85M | $69.23M | $1.41B | $1.13B | $1.24B | $1.23B | $1.14B | $1.11B |
| Accounts Payable | $374.82M | $363.56M | $339.73M | $357.04M | $1.38B | $1.25B | $1.34B | $1.38B | $1.22B | $1.17B |
| Current Assets | $588.50M | $547.87M | $2.13B | $2.30B | $2.21B | $2.02B | $2.12B | $2.33B | $2.24B | $2.10B |
| Total Assets | $2.42B | $2.45B | $4.04B | $4.15B | $4.86B | $4.66B | $5.08B | $5.30B | $5.21B | $5.09B |
| Current Liabilities | $1.20B | $947.08M | $2.47B | $2.67B | $1.96B | $1.87B | $1.93B | $2.13B | $1.93B | $1.89B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.88B | $2.91B | $4.47B | $4.44B | $4.29B | $4.09B | $4.21B | $4.44B | $4.31B | $4.17B |
| Stockholders' Equity | ($464.76M) | ($460.98M) | ($429.51M) | ($281.01M) | $570.98M | $565.23M | $874.59M | $860.70M | $894.87M | $924.17M |
| Retained Earnings | ($1.09B) | ($1.08B) | ($1.02B) | ($871.88M) | $1.02M | $6.02M | $302.14M | $314.91M | $346.82M | $368.71M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($35.07M) | - | - | - | ($35.07M) | - | - | - | ($52.96M) | - |
| Investing Cash Flow | $53.92M | - | - | - | ($48.20M) | - | - | - | ($1.87M) | - |
| Financing Cash Flow | $51.08M | - | - | - | $92.78M | - | - | - | $53.32M | - |
| CapEx | $45.79M | - | - | - | - | - | $61.52M | $45.80M | $46.00M | - |
| Free Cash Flow | ($80.86M) | - | - | - | - | - | - | - | ($98.96M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 44.3% | - | 46.2% | 47.6% | 20.0% | - | 20.6% | 20.4% | 20.5% | - |
| Operating margin | 2.7% | - | 3.8% | -5.8% | 0.0% | - | 0.9% | 0.8% | 0.4% | - |
| EBITDA margin | 12.6% | - | - | - | 2.3% | - | 3.2% | 3.2% | 3.2% | - |
| Net margin | -1.0% | - | -21.6% | -127.4% | -0.9% | - | -0.5% | -1.2% | -0.8% | - |
| Free cash flow margin | -12.9% | - | - | - | - | - | - | - | -3.8% | - |
| FCF / Net income | 12.50 | - | - | - | - | - | - | - | 4.52 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 40.7% | - | 38.1% | 39.3% | 17.6% | - | 17.3% | 17.6% | 18.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -0.3% | - | -3.7% | -20.9% | -0.5% | - | -0.3% | -0.6% | -0.4% | - |
| Return on equity | 1.4% | - | 35.0% | 309.3% | -4.4% | - | -1.5% | -3.7% | -2.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.49 | 0.58 | 0.86 | 0.86 | 1.13 | 1.08 | 1.09 | 1.09 | 1.16 | 1.11 |
| Quick ratio | 0.43 | 0.50 | 0.84 | 0.83 | 0.41 | 0.47 | 0.45 | 0.51 | 0.56 | 0.52 |
| Cash ratio | 0.28 | 0.30 | 0.01 | 0.01 | 0.03 | 0.03 | 0.02 | 0.11 | 0.13 | 0.13 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 0.7x | - | 0.9x | -1.5x | 0.0x | - | 0.7x | 0.6x | 0.3x | - |
| Equity multiplier | -5.20 | -5.32 | -9.40 | -14.78 | 8.51 | 8.24 | 5.81 | 6.16 | 5.82 | 5.51 |
| Liabilities / Assets | 1.19 | 1.19 | 1.11 | 1.07 | 0.88 | 0.88 | 0.83 | 0.84 | 0.83 | 0.82 |
| Efficiency | ||||||||||
| Asset turnover | 0.26 | - | 0.17 | 0.16 | 0.54 | - | 0.54 | 0.50 | 0.50 | - |
| Inventory turnover | 5.36 | - | 5.87 | 5.16 | 1.50 | - | 1.74 | 1.73 | 1.81 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 68d | - | 62d | 71d | 244d | - | 210d | 211d | 201d | - |
| Days payable outstanding | 391d | - | 331d | 365d | 239d | - | 226d | 237d | 214d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -76.1% | - | -74.4% | -74.5% | 0.7% | - | 5.0% | 4.2% | 3.6% | - |
| Revenue CAGR (3y) | -37.1% | - | -34.6% | -35.1% | 3.0% | - | 2.8% | 2.4% | 3.9% | - |
| Revenue CAGR (5y) | -23.0% | - | -20.4% | -17.7% | 4.4% | - | 2.6% | 1.5% | 1.2% | - |
| Gross profit growth (YoY) | -47.1% | - | -42.4% | -40.3% | -1.8% | - | 3.9% | 4.8% | 7.7% | - |
| Operating income growth (YoY) | 13710.5% | - | 9.4% | - | -98.7% | - | 1.5% | 87.3% | -1.1% | - |
| Net income growth (YoY) | 74.1% | - | -1076.8% | -2623.2% | -14.1% | - | -98.7% | -13.0% | 10.4% | - |
| EPS growth (YoY) | 75.0% | - | -1041.2% | -2590.5% | -10.3% | - | -112.5% | -13.5% | 9.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -36.2% | -38.8% | -1.4% | -4.0% | -3.2% | -2.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$2.76B totalDiabetes Product$783.37M · 28.4%
Sleep Therapy Product$740.05M · 26.8%
Home Respiratory Therapy Product$433.05M · 15.7%
Product And Service Other$288.19M · 10.4%
Ostomy$212.84M · 7.7%
Wound Care$188.51M · 6.8%
Urology$116.02M · 4.2%
Peer comparison
Same SIC group: Wholesale-Medical, Dental & Hospital Equipment & Supplies
Comparing OWENS & MINOR INC/VA/ against the 2 most active filers in the same SIC group.